Founded in 2009 and based in southern California, start-up [Epicardial Technologies Inc.] (ETI) is developing a potentially game-changing technology platform designed to enable physicians to more easily perform percutaneous, catheter-based ablation of common heart rhythm abnormalities, including atrial fibrillation (AF) and ventricular tachycardia (VT), from the inside or the outside (epicardial) surface of the heart, while protecting the structures surrounding the heart from serious damage or injury.
According to Kalyanam Shivkumar, MD, PhD, a founder and chief scientific advisor of Epicardial Technologies and also director of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?